Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11930
Title: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Authors: Andrews, Miles C;Behren, Andreas;Chionh, Fiona;Mariadason, John M;Vella, Laura J;Do, Hongdo;Dobrovic, Alexander;Tebbutt, Niall C;Cebon, Jonathan S
Affiliation: Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia.
Issue Date: 4-Nov-2013
Citation: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2013; 31(35): e448-51
Internal ID Number: 24190114
URI: http://ahro.austin.org.au/austinjspui/handle/1/11930
DOI: 10.1200/JCO.2013.50.4118
URL: http://www.ncbi.nlm.nih.gov/pubmed/24190114
Type: Journal Article
Subjects: Cell Proliferation.drug effects
Colonic Neoplasms.drug therapy.genetics.pathology
Humans
Imidazoles.therapeutic use
MAP Kinase Kinase 1.antagonists & inhibitors.metabolism
MAP Kinase Kinase 2.antagonists & inhibitors.metabolism
Male
Middle Aged
Mutation
Oximes.therapeutic use
Protein Kinase Inhibitors.therapeutic use
Proto-Oncogene Proteins.genetics
Proto-Oncogene Proteins B-raf.antagonists & inhibitors.metabolism
Pyridones.therapeutic use
Pyrimidinones.therapeutic use
Treatment Outcome
ras Proteins.genetics
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.